SIBNNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
SI-BONE, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$19.66−0.02 (-0.10%)
Close on Oct 19, 2026
- Market cap
- $874.42M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
79.6%−8.3 pts over 5 years
Operating margin
-11.1%+41.4 pts over 5 years
Net margin
-9.4%+50.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +20.2% | +23.6% | +22.3% | – | |
| Gross profit | +21.0% | +20.8% | +19.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -37.6% | -11.0% | |
| Return on assets | – | -25.7% | -8.1% | |
| Current ratio | – | 16.20 | 8.55 | |
| Debt to equity | – | 0.23 | 0.20 | |
| Net debt to EBITDA | – | 0.38× | 0.40× | |
| Interest coverage | – | -6.3× | -8.5× | |
| Inventory turnover | – | 1.6× | 1.3× | |
| Capex to revenue | – | 3.5% | 4.2% | |
| Diluted shares | – | 29M | 43M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Si-Bone generated $113.00M from operations and spent $42.61M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$113.00M
Used
$42.61M
Capital expenditure$42.61M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-9.4%
×Asset turnover0.86×
×Equity multiplier1.36×
=Return on equity, FY2025-11.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -9.4% | 0.86× | 1.36× | -11.0% |
| FY2024 | -18.5% | 0.73× | 1.37× | -18.4% |
| FY2023 | -31.2% | 0.72× | 1.45× | -32.4% |
| FY2022 | -57.6% | 0.61× | 1.50× | -52.6% |
| FY2021 | -62.8% | 0.44× | 1.36× | -37.2% |
| FY2020 | -59.5% | 0.43× | 1.46× | -37.6% |
| FY2019 | -57.1% | 0.53× | 1.67× | -50.1% |
| FY2018 | -31.5% | 0.64× | -4.45× | 89.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$18.90M
- Cash generatingOperating cash flow above zero-$675.00K
- Return on assets improvedROA up on the prior year-13.4% → -8.2%
- Earnings backed by cashOperating cash flow above net income-$675.00K vs -$18.90M
- Less leverageLong-term debt to assets fell15.4% → 14.9%
- Better liquidityCurrent ratio rose7.66 → 8.55
- No dilutionShare count did not rise41M → 43M
- Gross margin improvedGross margin up on the prior year79.03% → 79.57%
- More efficientAsset turnover rose0.73 → 0.87